Replimune Group Inc. Insider Trading
REPL
Insiders sold $4.11M and bought nothing on the open market.
7% of the selling was scheduled in advance under 10b5-1 plans. Chief Executive Officer Sushil Patel sold $1.06M on Nov 16, 6.9% of their stake, outside a plan. The last open-market buy by an executive or director was in Nov 2019.
Get an email when REPL's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Nov 16 | Konstantinos Xynos Chief Medical Officer | SoldNo plan | 16,198 | $21.60 | 350K | 7.2% | Form 4 |
| Nov 16 | Andrew Schwendenman Chief Accounting Officer | SoldNo plan | 2,148 | $21.60 | 46K | 2.2% | Form 4 |
| Nov 16 | Sushil Patel Chief Executive Officer | SoldNo plan | 49,026 | $21.60 | $1.06M | 6.9% | Form 4 |
| Nov 16 | Emily Luisa Hill Chief Financial Officer | SoldNo plan | 14,709 | $21.60 | 318K | 6.8% | Form 4 |
| Nov 9 | Joseph P Slattery Director | SoldNo plan | 5,200 | $21.80 | 113K | 78% | Form 4 |
| Nov 2 | Kapil Dhingra Director | SoldNo plan | 21,500 | $19.00 | 409K | 50% | Form 4 |
| Aug 17 | Emily Luisa Hill Chief Financial Officer | SoldNo plan | 9,256 | $14.28 | 132K | 4.1% | Form 4 |
| Aug 10 | Sushil Patel Chief Executive Officer | SoldNo plan | 39,341 | $12.97 | 510K | 5.3% | Form 4 |
| Aug 10 | Emily Luisa Hill Chief Financial Officer | SoldNo plan | 11,448 | $12.97 | 148K | 4.8% | Form 4 |
| Aug 10 | Konstantinos Xynos Chief Medical Officer | SoldNo plan | 11,447 | $12.97 | 148K | 4.9% | Form 4 |
| Aug 10 | Andrew Schwendenman Chief Accounting Officer | SoldNo plan | 7,632 | $12.97 | 99K | 7.1% | Form 4 |
| Jun 1 | Christopher Sarchi Chief Commercial Officer | Sold10b5-1 plan | 12,000 | $9.24 | 111K | 6.2% | Form 4 |
| May 18 | Konstantinos Xynos Chief Medical Officer | SoldNo plan | 14,023 | $5.08 | 71K | 5.6% | Form 4 |
| May 18 | Andrew Schwendenman Chief Accounting Officer | SoldNo plan | 7,894 | $5.08 | 40K | 6.9% | Form 4 |
| May 18 | Christopher Sarchi Chief Commercial Officer | SoldNo plan | 8,626 | $5.08 | 44K | 4.3% | Form 4 |
| May 18 | Philip Astley-Sparke Director | SoldNo plan | 17,657 | $5.08 | 90K | 1.2% | Form 4 |
| May 18 | Sushil Patel Chief Executive Officer | SoldNo plan | 37,324 | $5.08 | 190K | 4.8% | Form 4 |
| May 18 | Emily Luisa Hill Chief Financial Officer | SoldNo plan | 7,812 | $5.08 | 40K | 3.2% | Form 4 |
| Apr 2 | Christopher Sarchi Chief Commercial Officer | Sold10b5-1 plan | 6,500 | $8.01 | 52K | 4.1% | Form 4 |
| Dec 9, 2025 | Kapil Dhingra Director | SoldNo plan | 3,169 | $10.40 | 33K | 100% | Form 4 |
| Dec 2, 2025 | Sushil Patel Chief Executive Officer | Sold10b5-1 plan | 10,000 | $11.13 | 111K | 2.9% | Form 4 |
| Nov 17, 2025 | Christopher Sarchi Chief Commercial Officer | SoldNo plan | 5,208 | $9.10 | 47K | 4.1% | Form 4 |
| Nov 17, 2025 | Konstantinos Xynos Chief Medical Officer | SoldNo plan | 7,248 | $9.10 | 66K | 4.9% | Form 4 |
| Aug 15, 2025 | Emily Luisa Hill Chief Financial Officer | SoldNo plan | 9,154 | $5.37 | 49K | 6.4% | Form 4 |
| May 20, 2025 | Philip Astley-Sparke Director | SoldNo plan | 32,279 | $8.06 | 260K | 2.2% | Form 4 |
| May 20, 2025 | Konstantinos Xynos Chief Medical Officer | SoldNo plan | 7,952 | $8.06 | 64K | 5.1% | Form 4 |
| May 20, 2025 | Andrew Schwendenman Chief Accounting Officer | SoldNo plan | 3,287 | $8.05 | 26K | 4.6% | Form 4 |
| May 20, 2025 | Sushil Patel Chief Executive Officer | SoldNo plan | 25,105 | $8.06 | 202K | 6.8% | Form 4 |
| May 20, 2025 | Emily Luisa Hill Chief Financial Officer | SoldNo plan | 2,535 | $8.05 | 20K | 1.7% | Form 4 |
| May 20, 2025 | Christopher Sarchi Chief Commercial Officer | SoldNo plan | 3,749 | $8.05 | 30K | 2.8% | Form 4 |
| Dec 16, 2024 | Sushil Patel Chief Executive Officer | Sold10b5-1 plan | 10,000 | $12.42 | 124K | 4.7% | Form 4 |
- Nov 16No planKonstantinos XynosChief Medical Officer · sold 16,198 at $21.60350K7.2% of stake
- Nov 16No planAndrew SchwendenmanChief Accounting Officer · sold 2,148 at $21.6046K2.2% of stake
- Nov 16No planSushil PatelChief Executive Officer · sold 49,026 at $21.60$1.06M6.9% of stake
- Nov 16No planEmily Luisa HillChief Financial Officer · sold 14,709 at $21.60318K6.8% of stake
- Nov 9No planJoseph P SlatteryDirector · sold 5,200 at $21.80113K78% of stake
- Nov 2No planKapil DhingraDirector · sold 21,500 at $19.00409K50% of stake
- Aug 17No planEmily Luisa HillChief Financial Officer · sold 9,256 at $14.28132K4.1% of stake
- Aug 10No planSushil PatelChief Executive Officer · sold 39,341 at $12.97510K5.3% of stake
- Aug 10No planEmily Luisa HillChief Financial Officer · sold 11,448 at $12.97148K4.8% of stake
- Aug 10No planKonstantinos XynosChief Medical Officer · sold 11,447 at $12.97148K4.9% of stake
- Aug 10No planAndrew SchwendenmanChief Accounting Officer · sold 7,632 at $12.9799K7.1% of stake
- Jun 110b5-1 planChristopher SarchiChief Commercial Officer · sold 12,000 at $9.24111K6.2% of stake
- May 18No planKonstantinos XynosChief Medical Officer · sold 14,023 at $5.0871K5.6% of stake
- May 18No planAndrew SchwendenmanChief Accounting Officer · sold 7,894 at $5.0840K6.9% of stake
- May 18No planChristopher SarchiChief Commercial Officer · sold 8,626 at $5.0844K4.3% of stake
- May 18No planPhilip Astley-SparkeDirector · sold 17,657 at $5.0890K1.2% of stake
- May 18No planSushil PatelChief Executive Officer · sold 37,324 at $5.08190K4.8% of stake
- May 18No planEmily Luisa HillChief Financial Officer · sold 7,812 at $5.0840K3.2% of stake
- Apr 210b5-1 planChristopher SarchiChief Commercial Officer · sold 6,500 at $8.0152K4.1% of stake
- Dec 9, 2025No planKapil DhingraDirector · sold 3,169 at $10.4033K100% of stake
- Dec 2, 202510b5-1 planSushil PatelChief Executive Officer · sold 10,000 at $11.13111K2.9% of stake
- Nov 17, 2025No planChristopher SarchiChief Commercial Officer · sold 5,208 at $9.1047K4.1% of stake
- Nov 17, 2025No planKonstantinos XynosChief Medical Officer · sold 7,248 at $9.1066K4.9% of stake
- Aug 15, 2025No planEmily Luisa HillChief Financial Officer · sold 9,154 at $5.3749K6.4% of stake
- May 20, 2025No planPhilip Astley-SparkeDirector · sold 32,279 at $8.06260K2.2% of stake
- May 20, 2025No planKonstantinos XynosChief Medical Officer · sold 7,952 at $8.0664K5.1% of stake
- May 20, 2025No planAndrew SchwendenmanChief Accounting Officer · sold 3,287 at $8.0526K4.6% of stake
- May 20, 2025No planSushil PatelChief Executive Officer · sold 25,105 at $8.06202K6.8% of stake
- May 20, 2025No planEmily Luisa HillChief Financial Officer · sold 2,535 at $8.0520K1.7% of stake
- May 20, 2025No planChristopher SarchiChief Commercial Officer · sold 3,749 at $8.0530K2.8% of stake
- Dec 16, 202410b5-1 planSushil PatelChief Executive Officer · sold 10,000 at $12.42124K4.7% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with REPL
Held by ETFs
REPL is in 26 US ETFs. The largest of them, with REPL's weight in each:
Spot a number that looks wrong? Check it in REPL's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing REPL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.